Background
==========

Stroke is the second leading cause of death in people over 60 years of age, and the fifth leading cause of death among the 15--59 age group \[[@b1-medscimonit-21-1879]\]. Stroke is also the leading cause of morbidity and mortality in industrialized nations, and the leading cause of disability worldwide \[[@b2-medscimonit-21-1879]\]. Stroke is the second most common cause of death in China, and patients with acute cerebral infarction (ACI), also known as acute ischemic stroke, account for 60--80% of all the stroke patients \[[@b3-medscimonit-21-1879]--[@b5-medscimonit-21-1879]\]. Most ACIs are caused by an embolic or thrombotic occlusion of an intracranial artery \[[@b6-medscimonit-21-1879]\]. Dietary factors elevate ACI risk through their influence on blood pressure, thrombosis, insulin resistance, platelet function, oxidation and systemic inflammation \[[@b7-medscimonit-21-1879]\]. Arterial revascularization to restore antegrade perfusion to the ischemic territory remains the principal therapeutic approach in ACI \[[@b8-medscimonit-21-1879]\]. However, prevention and early intervention is critical for improved clinical outcomes, and in this context, the discovery of biomarkers useful in predicting ACI severity and clinical prognosis has received special attention in recent years \[[@b9-medscimonit-21-1879]\].

Neuron specific enolase (NSE) is one such biomarker. It is a dimeric isoenzyme of the glycolytic enzyme enolase and is mainly found in the neurons \[[@b10-medscimonit-21-1879]\]. Ectopic expression of NSE is used as an auxiliary test in diagnosis of small cell carcinoma of lung, neuroendocrine tumors and Alzheimer's disease \[[@b11-medscimonit-21-1879]--[@b13-medscimonit-21-1879]\]. Human soluble protein-100β (S-100β) is a low molecular weight calcium-binding protein and is found in glial cells of the central and peripheral nervous system \[[@b14-medscimonit-21-1879],[@b15-medscimonit-21-1879]\]. S-100β is mainly expressed in astrocytes but is also present in oligodendrocytes, microglia, neurons, and extracerebral tissues \[[@b16-medscimonit-21-1879]\], and elevated serum S-100β level is observed in cerebral infarction, traumatic brain injury, cerebral infarction or subarachnoid hemorrhage \[[@b17-medscimonit-21-1879],[@b18-medscimonit-21-1879]\]. The serum levels of NSE and S-100β are elevated after various types of brain damage, such as focal and global ischemia, head injury and hemorrhagic brain damage \[[@b19-medscimonit-21-1879]\]. Several previous studies showed that NSE and S-100β protein levels predict the clinical outcome of ACI, and NSE positively correlates with infarct volume in ACI patients \[[@b10-medscimonit-21-1879],[@b20-medscimonit-21-1879],[@b21-medscimonit-21-1879]\]. However, other studies failed to confirm the relationship between NSE and ACI severity \[[@b22-medscimonit-21-1879]\]. In order to address this issue with a larger dataset, we used meta-analysis approach to further investigate the clinical value of serum NSE and S-100β levels in ACI.

Material and Methods
====================

Literature search strategy
--------------------------

We searched PubMed, EBSCO, Ovid, SpringerLink, Web of Science, Embase, Wanfang, China National Knowledge Infrastructure (CNKI) and VIP Information databases for relevant studies published prior to September, 2014. We used combinations of terms to achieve optimal search sensitivity and specificity. Our search strategy was as follows: ("stroke" or "brain infarction" or "cerebral infarction" or "cerebral ischemic stroke" or "cerebral stroke" or "ischemic stroke" or "acute cerebral infarction"), ("phosphopyruvate hydratase" or "2-phospho-D-glycerate hydrolase" or "enolase" or "NSE" or "neuron-specific enolase" or "muscle specific enolase" or "nervous system specific enolase") and ("S100B protein, human" or "S100 beta protein, human").

Study selection
---------------

Our study inclusion criteria were: (1) studies that investigated the correlation of ACI with serum levels of NSE and S-100β; (2) case-control studies; (3) study subjects are patients with ACI in case group and healthy controls in control group; (4) studies providing complete information related to country, ethnicity, publication year, age, gender, detection method and sample size, and the outcome indicators were serum NSE and S-100β levels. The exclusion criteria were: (1) the diagnostic basis was undefined; (2) incomplete data was provided; (3) studies that were published repeatedly. In case of duplicate reports, we used data from the study that included the largest number of patients or individual patient data from each study when available. We contacted authors for clarification on the study sample or missing data.

Data extraction
---------------

Two investigators independently collected data using a standardized data abstraction form. We abstracted information associated to first author, publication year, country, language, ethnicity, age, gender, detection method, serum levels of NSE and S-100β. Any disagreements in data extraction were resolved through discussion with multiple investigators.

Statistical analysis
--------------------

All statistical analyses were performed using STATA software (Version 12.0, Stata Corporation, College Station, TX, USA). The correlation between serum levels of NSE and S-100β and ACI was measured by the standard mean difference (SMD) and 95% confidence interval (95%CI) with a random or fixed effects model. The overall effect size was detected by Z test \[[@b23-medscimonit-21-1879]\]. Heterogeneity among studies was evaluated by the Cochran's Q-statistic (if *P*\<0.05 heterogeneity existed) and *I^2^* test, which is an appraisement of the percentage of total variation across studies ranging from 0 to 100% \[[@b24-medscimonit-21-1879],[@b25-medscimonit-21-1879]\]. A random effects model was applied if there was significant heterogeneity (*P*\<0.05 or *I^2^*\>50%), otherwise, a fixed effects model was utilized \[[@b26-medscimonit-21-1879]\]. Univariate and multiple meta-regression analyses were used to estimate the source of heterogeneity, and Monte Carlo simulation (MCS) was performed to verify the results \[[@b27-medscimonit-21-1879],[@b28-medscimonit-21-1879]\]. Sensitivity analysis was employed by deleting one included study at a time to evaluate the influence of one single study on the overall results. The publication bias that assesses the reliability of the result was evaluated by funnel plot and the Egger test \[[@b29-medscimonit-21-1879]\].

Results
=======

Study selection and study characteristics
-----------------------------------------

Our search strategy retrieved 117 citations after removal of duplicates. Forty three papers were remaining after excluding 2 duplicates, 22 animal studies, 8 letters, reviews, or meta-analyses and 44 studies unrelated to the research topic. We further excluded 4 cohort studies, 12 studies not relevant to NSE and S-100β, 11 studies unrelated to ACI, and 3 studies that had insufficient information. Finally, 13 case-control studies published between 2002 and April 2014 \[[@b2-medscimonit-21-1879],[@b30-medscimonit-21-1879]--[@b41-medscimonit-21-1879]\], containing 911 ACI patients in case group and 686 healthy controls in control group, were finally selected for this meta-analysis. Among these 13 studies, study subjects in 11 trials were Asians, 2 trials were performed in Caucasians. A total of 9 studies were from China and 1 each from India, Korea, Cuba, Belgium. Sample sizes ranged from 58 to 236. Serum levels of NSE and S-100β were detected by enzyme linked immunosorbent assay (ELISA) or electro-chemiluminescence immunoassay (ECLI). The baseline characteristics all included case-control studies are shown in [Table 1](#t1-medscimonit-21-1879){ref-type="table"}.

Correlation between ACI and serum levels of NSE
-----------------------------------------------

A total of 13 studies reported serum levels of NSE in ACI patients. Heterogeneity test suggested that heterogeneity existed across studies (*I^2^*=95.3%, *P*\<0.001), thus a random effects model was applied. The result of this meta-analysis revealed that serum levels of NSE were significantly higher in ACI patients compared to control group, and the difference was statistically significant (SMD=1.96, 95%CI=1.83\~2.09, *P*\<0.001) ([Figure 1](#f1-medscimonit-21-1879){ref-type="fig"}). Additionally, subgroup analysis based on ethnicity indicated that serum levels of NSE were markedly higher in ACI patients, compared to the control group, in both Asians and Caucasians (Asian: SMD=2.11, 95%CI=1.96\~2.25, *P*\<0.001; Caucasian: SMD=1.32, 95%CI=1.02\~1.61, *P*\<0.001). A subgroup analysis based on sample size showed that serum levels of NSE in ACI patients of both large sample size (n≥100) and small sample size (n\<100) were notably higher than the control group (large sample size: SMD=2.01, 95%CI=1.86\~2.17, *P*\<0.001; small sample size: SMD=1.80, 95%CI=1.55\~2.05, *P*\<0.001) ([Figure 2](#f2-medscimonit-21-1879){ref-type="fig"}). Univariate meta-regression analysis suggested that publication year, country, ethnicity and sample size were not the main sources of heterogeneity or the critical factors in influencing the overall effect size (*P*\>0.05) ([Figure 3A](#f3-medscimonit-21-1879){ref-type="fig"}). Multiple meta-regression analysis also indicated that year of publication, country, ethnicity, and sample size were not the sources of heterogeneity ([Table 2](#t2-medscimonit-21-1879){ref-type="table"}).

Correlation between ACI and serum levels of S-100β
--------------------------------------------------

Twelve studies investigated the serum levels of S-100β in ACI patients. There was no heterogeneity among these studies (*I^2^*=98.5%, *P*\<0.001), thus a fixed-effects model was performed. Results of the meta-analysis suggested that the serum levels of S-100β in ACI patients were higher than in healthy controls (SMD=2.69, 95%CI=2.51\~2.86, *P*\<0.001) ([Figure 1](#f1-medscimonit-21-1879){ref-type="fig"}). Additionally, subgroup analysis by ethnicity indicated that serum levels of S-100β in ACI patients was markedly higher than the control group in Asians (SMD=2.84, 95%CI=2.66\~3.02, *P*\<0.001), while no significant differences in S-100β levels were observed in a Caucasian population between ACI patients and the control group (SMD=−0.56, 95%CI=−1.37\~0.24, *P*=0.172). Subgroup analysis by sample size showed that the serum levels of S-100β in ACI patients in both large sample size (n≥100) and small sample size (n\<100) were notably higher than in the control group (large sample size: SMD=2.90, 95%CI=2.69\~3.12, *P*\<0.001; small sample size: SMD=2.33, 95%CI=2.05\~2.61, *P*\<0.001) ([Figure 2](#f2-medscimonit-21-1879){ref-type="fig"}). Univariate meta-regression analysis suggested that publication year, country, ethnicity and sample size were not the main sources of heterogeneity or the critical factors in affecting the overall effect size (*P*\>0.05) ([Figure 3B](#f3-medscimonit-21-1879){ref-type="fig"}). Multiple meta-regression analysis also indicated that publication year, country, ethnicity, and sample size were not the sources of heterogeneity ([Table 3](#t3-medscimonit-21-1879){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analysis suggested that no single study affected the statistical significance of overall results ([Figure 4](#f4-medscimonit-21-1879){ref-type="fig"}). *P*\<0.05 suggested there was publication bias among studies. Both the summary of funnel plot and Egger test showed no evident publication bias in NSE and S-100β levels between ACI patients and control group (NSE: *P*=0.459; S-100β: *P*=0.314) ([Figure 5](#f5-medscimonit-21-1879){ref-type="fig"}).

Discussion
==========

In this meta-analysis, we investigated the clinical value of NSE and S-100β in ACI patients, based on the data extracted from previous studies. We found that serum levels of NSE and S-100β in ACI patients were significantly higher than in the control group, suggesting that NSE and S-100β might be reliable markers for ACI. S-100β is a dimeric calcium-binding protein with α and β subunits. The β subunit is highly specific to the brain and is synthesized in glial cells throughout the central nervous system \[[@b42-medscimonit-21-1879]\]. Depending on its concentrations in the extracellular space, S-100β may either be beneficial for recovery after brain injury, or become neurotoxic \[[@b43-medscimonit-21-1879]\]. At normal concentrations, in the nanomolar range, S-100β stimulates neurite outgrowth, glial cell proliferation, and regeneration of injured nerves. Its neuroprotective function also includes enhancing neuronal cell maintenance, preventing motor neuron degeneration, and enhancing the survival of neurons \[[@b44-medscimonit-21-1879]\]. However, in the micromolar range, the excessive levels of S-100β result in production of reactive oxidative species, cytochrome C release, and activation of the caspase cell death cascade, leading to induction of apoptosis \[[@b44-medscimonit-21-1879],[@b45-medscimonit-21-1879]\]. S-100β protein can be detected in very low amounts in blood in normal healthy individuals. In acute and chronic brain damage, glial cells respond to the injury by increasing S-100β production; consequently, higher levels of this protein are seen in the serum and cerebrospinal fluid (CSF) under such conditions \[[@b35-medscimonit-21-1879]\]. The intracellular S-100β may enter the blood circulation either directly through the disrupted blood-brain barrier or first into CSF and subsequently into the blood through the arachnoid villi \[[@b46-medscimonit-21-1879]\]. In contrast to astrocyte-derived S-100β protein, NSE originates predominantly from neurons \[[@b47-medscimonit-21-1879]\]. NSE concentration strongly correlates with the volume of infarcted brain areas, and is an indicator of the severity of clinical features, such as disability. Neuronal injury results in the release of intracellular NSE from injured neurons into CSF and blood circulation \[[@b30-medscimonit-21-1879]\]. Our results suggest that serum NSE levels are tightly associated with ACI, consistent with a previous study which reported that NSE concentrations in was serum correlated with clinical outcomes in stroke and neurotrauma patients \[[@b48-medscimonit-21-1879]\]. Additionally, we also predicted that the serum levels of NSE and S100B also could be good predictive indicators in the treatment of ACI, as a previous study reported by García S et al. that suggested serum concentrations of NSE and S100B after acute stroke might be clinically relevant for predicting the outcome of neurological function and post-stroke depression \[[@b21-medscimonit-21-1879]\]. Furthermore, the results of another study by Kaca-Oryńska M et al. demonstrated that significant differences in NSE and S100B levels existed between stroke patients and the control group, but only the S100B protein level was associated with stroke volume, neurological status at admission, and the functional outcome compared with NSE \[[@b49-medscimonit-21-1879]\].

Subgroup analysis by ethnicity revealed that the serum levels of NSE in Asian and Caucasian ACI patients were significantly higher than in healthy controls. A second subgroup analysis indicated that in Asian populations, the serum level of S-100β in ACI patients was markedly higher than in healthy controls, while this difference was not statistically significant in Caucasian populations. Different regions, life-styles, and ethnicities may have underlying variations that could have contributed to this result. Subgroup analysis by sample size suggested that in both large and small sample sizes, the serum levels of NSE and S-100β were markedly higher in ACI patients compared to healthy controls, further confirming the main result of the present meta-analysis.

When interpreting our results, several limitations should be considered. First, 11 of the total 13 trials were in Asian populations, and this might bias the overall results to some extent. However, there was also statistical evidence for the clinical value in diagnosis of ACI in Asian populations. Second, the different detection methods may vary in specificity and sensitivity of S-100β and NSE measurement, and thus may bias the comparisons and results. Third, we could not perform sensitivity analyses related to age, sex, life-style variables, or family history, due to the varied data presentations or absence of the data in the included studies. Finally, other neurological diseases and risky behavior also influence serum S-100β protein concentrations \[[@b50-medscimonit-21-1879],[@b51-medscimonit-21-1879]\].

Conclusions
===========

Serum levels of NSE and S-100β were significantly higher in ACI patients in Asian populations compared to their healthy counterparts, suggesting that the 2 proteins strongly correlate with ACI and could be used as important biological indicators in diagnosis and treatment of ACI in Asians.
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###### 

Baseline characteristics of all included studies.

  First author        Year   Country   Sample size   Gender (M/F)   Age (years)   Method                     
  ------------------- ------ --------- ------------- -------------- ------------- ------------ ------------- -------
  Yu WH               2014   China     Large         72/46          70/48         48\~79       46\~75        ELISA
  Singh HV            2013   India     Large         70/30          67/34         59.71±12.6   61.31±12.37   ELISA
  An SA               2013   Korea     Large         101/87         37/53         66±11        61±9          ELISA
  Lv LZ               2012   China     Large         45/33          26/19         36\~73       55.9          ELISA
  Gonzalez Garcia S   2012   Cuba      Large         23/38          46/33         32\~88       30\~98        ELISA
  Wang QF             2010   China     Small         --             25/15         --           44\~73        ELISA
  Brouns R            2010   Belgium   Large         50/39          18/17         71.1±13.2    68.1±12.5     ECLIA
  Su XH               2009   China     Large         24/21          16/15         48\~69       45\~68        ELISA
  Zhang XN            2008   China     Small         --             15/10         --           45\~78        ECLIA
  Ma XN               2007   China     Small         --             22/18         --           59.85±8.24    CLIA
  Li Z                2007   China     Small         34/23          12/8          60.2±8.7     48.4±12.3     ECLIA
  Cao GB              2006   China     Small         27/31          --            46\~68       26\~65        ELISA
  Gao D               2002   China     Small         28/17          19/13         64.2±9.5     62.8±7.8      ELISA

M -- male; F -- female; ELISA -- enzyme linked immunosorbent assay; ECLI -- electro-chemiluminescence immunoassay.

###### 

Meta-regression analyses of potential source of heterogeneity (NSE).

  Heterogeneity factors   Coefficient   SE      t       *P*     95% CI   
  ----------------------- ------------- ------- ------- ------- -------- --------
  Year                    0.0960        0.246   0.39    0.937   −0.472   0.664
  Country                 −0.687        1.254   −0.55   0.863   −3.578   2.204
  Ethnicity               0.971         4.310   0.23    0.987   −8.967   10.909
  Sample                  −0.000        0.014   −0.01   1.000   −0.034   0.034

NSE -- neuron specific enolase; SE -- standard error; CI -- confidence interval; LL -- lower limit; UL -- upper limit.

###### 

Meta-regression analyses of potential source of heterogeneity (S-100β).

  Heterogeneity factors   Coefficient   SE       t       *P*     95% CI    
  ----------------------- ------------- -------- ------- ------- --------- --------
  Year                    0.244         0.576    0.42    0.925   −1.117    1.605
  Country                 −8.371        4.550    −1.84   0.264   −19.128   2.387
  Ethnicity               17.266        11.465   1.51    0.366   −9.843    44.376
  Sample                  0.018         0.031    0.57    0.867   −0.056    0.091

S-100β -- human soluble protein-100β; SE -- standard error; CI -- confidence interval; LL -- lower limit; UL -- upper limit.
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